AbbVie
ABBV
#25
Rank
NZ$685.36 B
Marketcap
NZ$387.78
Share price
0.98%
Change (1 day)
31.61%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Total debt

Total debt on the balance sheet as of September 2025 : NZ$118.38 Billion

According to AbbVie's latest financial reports the company's total debt is NZ$118.38 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

AbbVie - Total debt on balance sheet (from 2011 to 2025)

Total debt by year

Year Total debt Change
2024-12-31NZ$119.05 B26.78%
2023-12-31NZ$93.90 B-5.77%
2022-12-31NZ$99.65 B-11.23%
2021-12-31NZ$112.26 B-5.87%
2020-12-31NZ$119.26 B20.37%
2019-12-31NZ$99.07 B64.87%
2018-12-31NZ$60.09 B14.21%
2017-12-31NZ$52.61 B-1.07%
2016-12-31NZ$53.18 B14.94%
2015-12-31NZ$46.27 B142.08%
2014-12-31NZ$19.11 B6.69%
2013-12-31NZ$17.91 B-5.95%
2012-12-31NZ$19.05 B30875.84%
2011-12-31NZ$61.5 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
NZ$104.78 B-11.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$87.89 B-25.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$73.20 B-38.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$94.00 B-20.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$42.95 B-63.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$11.34 B-90.41%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$41.09 B-65.29%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$56.19 B-52.53%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$0.73 B-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA